Alex Thompson CFA
Stock Analyst at Stifel Nicolaus
(4.97)
# 70
Out of 4,707 analysts
263
Total ratings
71%
Success rate
46.9%
Average return
Main Sectors:
Stocks Rated by Alex Thompson CFA
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EVMN Evommune | Maintained: Buy | $30 | $13.08 | +129.36% | 4 | Sep 9, 2026 | |
| ANAB AnaptysBio | Rated: Hold | n/a | $56.60 | - | 12 | Sep 8, 2026 | |
| ASND Ascendis Pharma | Maintained: Buy | $328 → $326 | $270.09 | +20.70% | 17 | Sep 1, 2026 | |
| SEPN Septerna | Maintained: Buy | $49 → $46 | $37.37 | +23.09% | 3 | Aug 16, 2026 | |
| VRDN Viridian Therapeutics | Maintained: Buy | $40 | $23.17 | +72.64% | 19 | Aug 13, 2026 | |
| SYRE Spyre Therapeutics | Maintained: Buy | $123 | $90.79 | +35.48% | 20 | Aug 13, 2026 | |
| DNTH Dianthus Therapeutics | Maintained: Buy | $133 | $109.13 | +21.87% | 13 | Aug 13, 2026 | |
| KYMR Kymera Therapeutics | Maintained: Buy | $132 | $116.47 | +13.33% | 11 | Aug 13, 2026 | |
| CGEM Cullinan Therapeutics | Maintained: Buy | $28 | $21.69 | +29.09% | 7 | Aug 13, 2026 | |
| JBIO Jade Biosciences | Maintained: Buy | $40 | $19.45 | +105.66% | 3 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $44 | $10.58 | +315.88% | 6 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $49 → $57 | $39.57 | +44.05% | 17 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $62 | $66.07 | -6.16% | 31 | Aug 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $1,255 → $1,282 | $1,007.07 | +27.30% | 30 | Jul 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $68 | $39.12 | +73.82% | 7 | Jul 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 | $2.20 | +127.27% | 4 | Jul 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $150 | $94.31 | +59.05% | 10 | Jun 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $2.41 | +107.47% | 2 | May 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $36 → $39 | $19.71 | +97.87% | 6 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $2 → $4 | $6.06 | -33.99% | 13 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $13 → $19 | $14.94 | +27.18% | 8 | Mar 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $32 → $3 | $1.14 | n/a | 17 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $23 | $11.96 | n/a | 2 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $34 | $38.74 | n/a | 1 | Aug 8, 2023 |
Evommune
Sep 9, 2026
Maintained: Buy
Price Target: $30
Current: $13.08
Upside: +129.36%
AnaptysBio
Sep 8, 2026
Rated: Hold
Price Target: n/a
Current: $56.60
Upside: -
Ascendis Pharma
Sep 1, 2026
Maintained: Buy
Price Target: $328 → $326
Current: $270.09
Upside: +20.70%
Septerna
Aug 16, 2026
Maintained: Buy
Price Target: $49 → $46
Current: $37.37
Upside: +23.09%
Viridian Therapeutics
Aug 13, 2026
Maintained: Buy
Price Target: $40
Current: $23.17
Upside: +72.64%
Spyre Therapeutics
Aug 13, 2026
Maintained: Buy
Price Target: $123
Current: $90.79
Upside: +35.48%
Dianthus Therapeutics
Aug 13, 2026
Maintained: Buy
Price Target: $133
Current: $109.13
Upside: +21.87%
Kymera Therapeutics
Aug 13, 2026
Maintained: Buy
Price Target: $132
Current: $116.47
Upside: +13.33%
Cullinan Therapeutics
Aug 13, 2026
Maintained: Buy
Price Target: $28
Current: $21.69
Upside: +29.09%
Jade Biosciences
Aug 13, 2026
Maintained: Buy
Price Target: $40
Current: $19.45
Upside: +105.66%
Aug 13, 2026
Maintained: Buy
Price Target: $44
Current: $10.58
Upside: +315.88%
Aug 11, 2026
Maintained: Buy
Price Target: $49 → $57
Current: $39.57
Upside: +44.05%
Aug 9, 2026
Maintained: Hold
Price Target: $62
Current: $66.07
Upside: -6.16%
Jul 28, 2026
Maintained: Buy
Price Target: $1,255 → $1,282
Current: $1,007.07
Upside: +27.30%
Jul 22, 2026
Maintained: Buy
Price Target: $68
Current: $39.12
Upside: +73.82%
Jul 6, 2026
Maintained: Buy
Price Target: $5
Current: $2.20
Upside: +127.27%
Jun 29, 2026
Maintained: Buy
Price Target: $150
Current: $94.31
Upside: +59.05%
May 28, 2026
Reiterated: Buy
Price Target: $5
Current: $2.41
Upside: +107.47%
May 15, 2026
Maintained: Buy
Price Target: $36 → $39
Current: $19.71
Upside: +97.87%
May 8, 2026
Maintained: Hold
Price Target: $2 → $4
Current: $6.06
Upside: -33.99%
Mar 1, 2026
Maintained: Hold
Price Target: $13 → $19
Current: $14.94
Upside: +27.18%
Mar 3, 2025
Downgraded: Hold
Price Target: $32 → $3
Current: $1.14
Upside: n/a
Nov 7, 2024
Reiterated: Buy
Price Target: $23
Current: $11.96
Upside: n/a
Aug 8, 2023
Initiated Coverage: Buy
Price Target: $34
Current: $38.74
Upside: n/a